InVivo slides again as CFO bolts, spinal study pends

It's shaping up to be a rough year for InVivo Therapeutics ($NVIV): Two weeks after the company watched its shares take a 40% plunge, its stock price tanked again thanks to an abrupt C-level resignation and a last-minute conference pullout.

CFO Sean Moran tendered his resignation on Monday, InVivo said in a regulatory filing, and the company has canceled its plans to present at this week's Rodman and Renshaw Healthcare Conference, news that sent its share price down another 34%, bottoming out at $1.32 on Thursday morning.

Moran's unexplained resignation follows last month's departure of long-time CEO Frank Reynolds and the bombshell that its much-hyped biopolymer scaffolding for spinal injuries has been delayed indefinitely.

In August, the FDA approved InVivo's plan for a first-in-human trial under the Humanitarian Device Exemption, but the conditions require it to enroll just one patient every three months, running each one by the agency. Thus, InVivo can't start until the first quarter of next year, and the total enrollment will take at least 21 months, putting commercialization far in the future.

InVivo's stock price has slipped more than 75% since July, when the company believed it was well on its way to taking a quick trip through the FDA process and capitalizing on a first-of-its-kind implant. Now, the company is searching for a CEO and CFO, with Vivus ($VVUS) board chairman Michael Astrue serving as interim chief.

- check out InVivo's SEC filing

Suggested Articles

Sherlock Biosciences teamed up with Cepheid to help develop its CRISPR-based molecular diagnostic tech in oncology, infections and the coronavirus.

The spine surgery company ATEC has moved to acquire Paris-based EOS imaging, makers of FDA-cleared scanners and 3D orthopedic planning software.

Digital molecule designer Insilico Medicine has launched a new preclinical research program focused on treatments for brain cancer.